Literature DB >> 2183683

Dopamine cell replacement: Parkinson's disease.

D M Yurek1, J R Sladek.   

Abstract

Significant progress in neural transplantation has been observed over the last several decades. As a neuroanatomical tool, neural transplantation studies are able to examine the mechanisms involved in the development and integration of neurons into the complex neural circuitries of the brain. Today, embryonic neural tissue can be successfully transplanted as solid tissue chunks or as dissociated cell suspensions. Within the parenchyma of the brain, transplanted embryonic neurons develop mature morphology and do not appear to invoke an immunological response by the lost immune system. Not only do these neurons exhibit robust development but there is also evidence that transplanted neurons restore some degree of function to neurologically damaged circuitry; however, the extent of reintegration into the host neural circuitry still remains unclear. Moreover, the long-term survival and functioning of transplanted nerve cells also remains an unanswered question. Advances in the emerging field of genetic engineering may eventually lead to genetically modified neurons that are capable of synthesizing neurotrophic factors or missing neurotransmitters and restoring function in brain-damaged areas. The use of neural transplantation to replace damaged nerve cells in neurodegenerative disorders, such as Alzheimer's or Parkinson's disease, is promising based on our current knowledge. However, our basic scientific knowledge of neural transplants is incomplete and warrants a prudent approach toward application of neural transplantation techniques in clinical research.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2183683     DOI: 10.1146/annurev.ne.13.030190.002215

Source DB:  PubMed          Journal:  Annu Rev Neurosci        ISSN: 0147-006X            Impact factor:   12.449


  21 in total

1.  Functional regeneration in a rat Parkinson's model after intrastriatal grafts of glial cell line-derived neurotrophic factor and transforming growth factor beta1-expressing extra-adrenal chromaffin cells of the Zuckerkandl's organ.

Authors:  E F Espejo; M C Gonzalez-Albo; J P Moraes; F El Banoua; J A Flores; I Caraballo
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

2.  Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector.

Authors:  Mei Sun; Guo-Rong Zhang; Lingxin Kong; Courtney Holmes; Xiaodan Wang; Wei Zhang; David S Goldstein; Alfred I Geller
Journal:  Hum Gene Ther       Date:  2003-03-20       Impact factor: 5.695

3.  Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival.

Authors:  Caryl E Sortwell; William J Bowers; Scott E Counts; Mark R Pitzer; Matthew F Fleming; Susan O McGuire; Kathleen A Maguire-Zeiss; Howard J Federoff; Timothy J Collier
Journal:  Brain Res       Date:  2006-12-28       Impact factor: 3.252

Review 4.  Getting into the brain: approaches to enhance brain drug delivery.

Authors:  Mayur M Patel; Bhoomika R Goyal; Shraddha V Bhadada; Jay S Bhatt; Avani F Amin
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  Establishment and characterization of immortalized clonal cell lines from fetal rat mesencephalic tissue.

Authors:  K N Prasad; E Carvalho; S Kentroti; J Edwards-Prasad; C Freed; A Vernadakis
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-09       Impact factor: 2.416

Review 6.  Behavioural consequences of neural transplantation.

Authors:  S B Dunnett
Journal:  J Neurol       Date:  1994-12       Impact factor: 4.849

Review 7.  Transplantation strategies for the analysis of brain development and repair.

Authors:  M Cunningham; R McKay
Journal:  J Neurol       Date:  1994-12       Impact factor: 4.849

8.  Foetal nigral cell suspension grafts influence dopamine release in the non-grafted side in the 6-hydroxydopamine rat model of Parkinson's disease: in vivo voltammetric data.

Authors:  C D Earl; T Reum; J X Xie; J Sautter; A Kupsch; W H Oertel; R Morgenstern
Journal:  Exp Brain Res       Date:  1996-04       Impact factor: 1.972

Review 9.  Neurotrophic factors for the investigation and treatment of movement disorders.

Authors:  Justo Garcia De Yébenes; Marina Sánchez; Maria Angeles Mena
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  Chromaffin cell xenografts in the rat neocortex can produce antidepressive activity in the forced swimming test.

Authors:  C E Sortwell; G D Pappas; J Sagen
Journal:  Exp Brain Res       Date:  1995       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.